Updated efficacy results from the phase I cervical cancer cohort of BAT8008, a TROP-2–directed antibody-drug conjugate, in patients with advanced cervical cancer.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Fujian Medical University, Fujian Provincial Cancer Hospital, Second Affiliated Hospital of Anhui Medical University, Chongqing University, Chongqing Cancer Hospital, Zhangzhou Municipal Hospital of Fujian Province, Zhejiang Cancer Hospital, Jinan Central Hospital, Shandong First Medical University, First Affiliated Hospital of Xinxiang Medical University, Shanxi Provincial Cancer Hospital, Third Hospital of Nanchang, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Xiangyang Central Hospital, Hubei University of Medicine, Taihe Hospital
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162532339